Literature DB >> 23953881

Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.

Ryuko Nakayama1, Junya Kuroda2, Nobuko Taniyama3, Mio Yamamoto-Sugitani1, Sayori Wada3, Miki Kiyota1, Shinsuke Mizutani1, Yoshiaki Chinen1, Yosuke Matsumoto1, Hisao Nagoshi1, Yuji Shimura1, Tsutomu Kobayashi1, Shigeo Horiike1, Kenji Sato3, Masafumi Taniwaki1.   

Abstract

Galectin-3 is induced in chronic myelogenous leukemia (CML) cells by co-culture with bone marrow stromal cells, making paracrine growth promotion of CML cells in conditioned medium (CM) from galectin-3 overexpressing CML cells more potent. We used gel filtration chromatography to demonstrate that the bovine SERPINA1-fetal bovine serum albumin (BSA) complex was specifically suppressed in CM from galectin-3 overexpressing cells. The SERPINA1-BSA complex as well as human plasma SERPINA1 inhibited the growth of CML cells, while exogenous galectin-3 partly offset this effect. These findings suggest that galectin-3 overexpression promotes paracrine growth of CML cells by interfering with the action of the growth inhibitory SERPINA1-albumin complex.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow stromal cell; Chronic myelogenous leukemia; Galectin-3; SERPINA1

Mesh:

Substances:

Year:  2013        PMID: 23953881     DOI: 10.1016/j.leukres.2013.07.026

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Galectins as therapeutic targets for hematological malignancies: a hopeful sweetness.

Authors:  Camilo Pena; Leonardo Mirandola; Jose A Figueroa; Nattamol Hosiriluck; Natallia Suvorava; Kayley Trotter; Adair Reidy; Rahman Rakhshanda; Drew Payne; Marjorie Jenkins; Fabio Grizzi; Lauren Littlefield; Maurizio Chiriva-Internati; Everardo Cobos
Journal:  Ann Transl Med       Date:  2014-09

3.  Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Christopher B Benton; Ahmed AlRawi; Jared K Burks; Wendy Schober; James Rolke; George Tidmarsh; Numsen Hail; R Eric Davis; Michael Andreeff
Journal:  Biochim Biophys Acta       Date:  2015-12-17

Review 4.  Extracellular galectin-3 in tumor progression and metastasis.

Authors:  Anneliese Fortuna-Costa; Angélica M Gomes; Eliene O Kozlowski; Mariana P Stelling; Mauro S G Pavão
Journal:  Front Oncol       Date:  2014-06-16       Impact factor: 6.244

5.  LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.

Authors:  Peter P Ruvolo; Chenyue W Hu; Yihua Qiu; Vivian R Ruvolo; Robin L Go; Stefan E Hubner; Kevin R Coombes; Michael Andreeff; Amina A Qutub; Steven M Kornblau
Journal:  EBioMedicine       Date:  2019-05-16       Impact factor: 8.143

6.  Generation of human islet cell type-specific identity genesets.

Authors:  Léon van Gurp; Leon Fodoulian; Daniel Oropeza; Kenichiro Furuyama; Eva Bru-Tari; Anh Nguyet Vu; John S Kaddis; Iván Rodríguez; Fabrizio Thorel; Pedro L Herrera
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

Review 7.  Targeting Gas6/TAM in cancer cells and tumor microenvironment.

Authors:  Guiling Wu; Zhiqiang Ma; Yicheng Cheng; Wei Hu; Chao Deng; Shuai Jiang; Tian Li; Fulin Chen; Yang Yang
Journal:  Mol Cancer       Date:  2018-01-31       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.